Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series.

"SA declares no conflicts of interest. KG has received grants from Pfizer Inc., Galapagos, and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis, and Takeda; and speaker’s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts, all outside the submitted work. CP has served as a speaker for Tillotts, as an advisor for Chemomab and Pliant, and received research grants from Gilead and Perspectum, all outside the submitted work. ML received consultancy/lecture fees from Abbvie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen-Cilag, Johnson & Johnson, Medtronic, Pfizer, Takeda, and Tillotts. He is a central reader for Alimentiv and received grants from Galapagos, Pfizer, and ZonMW, all outside the submitted work. GD has served as a speaker for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, and Takeda; consultancy fees for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity and Protagonist and data monitoring board for Galapagos, Astrazeneca, and Seres Health, all outside the submitted work."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."